HomeHeadlinesUS FDA proposes to exclude Semaglutide (NOVOB DC), Tirzepatide (LLY), and Liraglutide (NOVOB DC) on 503B bulks listAPRIL 30, 2026 AT 01:23 PMUS FDA proposes to exclude Semaglutide (NOVOB DC), Tirzepatide (LLY), and Liraglutide (NOVOB DC) on 503B bulks listByNewsquawk StaffImportanceLevel 1#ELI LILLY & CO#LLY.US#NOVO NORDISK A/S#NOVOB.DC#FDA#IMPORTANT#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#GLOBAL EQUITIES
APRIL 30, 2026 AT 01:23 PMUS FDA proposes to exclude Semaglutide (NOVOB DC), Tirzepatide (LLY), and Liraglutide (NOVOB DC) on 503B bulks listByNewsquawk StaffImportanceLevel 1#ELI LILLY & CO#LLY.US#NOVO NORDISK A/S#NOVOB.DC#FDA#IMPORTANT#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#GLOBAL EQUITIES
